KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EPS (Basic) (2016 - 2025)

Biogen has reported EPS (Basic) over the past 17 years, most recently at -$0.33 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.33 for Q4 2025, down 118.03% from a year ago — trailing twelve months through Dec 2025 was $8.83 (down 21.3% YoY), and the annual figure for FY2025 was $8.83, down 21.23%.
  • EPS (Basic) for Q4 2025 was -$0.33 at Biogen, down from $3.18 in the prior quarter.
  • Over the last five years, EPS (Basic) for BIIB hit a ceiling of $7.86 in Q3 2022 and a floor of -$0.47 in Q3 2023.
  • Median EPS (Basic) over the past 5 years was $2.7 (2021), compared with a mean of $2.98.
  • Biggest five-year swings in EPS (Basic): soared 668.09% in 2024 and later tumbled 118.03% in 2025.
  • Biogen's EPS (Basic) stood at $2.51 in 2021, then skyrocketed by 52.99% to $3.84 in 2022, then tumbled by 55.21% to $1.72 in 2023, then rose by 6.4% to $1.83 in 2024, then tumbled by 118.03% to -$0.33 in 2025.
  • The last three reported values for EPS (Basic) were -$0.33 (Q4 2025), $3.18 (Q3 2025), and $4.33 (Q2 2025) per Business Quant data.